BioSpace News Archive

De-risking and Self Advocacy Key to Changing Women’s Healthcare R&D

Despite an anticipated revenue opportunity of $24.48 billion by 2027, a fraction of R&D funding is currently allocated to this space. BioSpace spoke with Organon’s Sandy Milligan about the challenges and progress.

August 25, 2022
·
5 min read
·
Abbey Glasure
Pharm Country

Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection

Century Therapeutics, Inc. announced today that the company has been notified by the U.S. Food and Drug Administration (FDA) that the Company’s ELiPSE-1 clinical study may proceed to assess CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies.

August 25, 2022
·
8 min read
Genetown

Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)

Stoke Therapeutics today announced enrollment of the first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy (ADOA).

August 25, 2022
·
7 min read
Drug Development

Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies

Aptinyx Inc. today announced the completion of enrollment of 99 patients in the company’s ongoing Phase 2 study of NYX-458 in cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.

August 25, 2022
·
5 min read
Deals

Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share

Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per share to holders of the Company’s Common Stock.

August 25, 2022
·
2 min read
Pharm Country

Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium

Oyster Point Pharma, Inc. today announced the presentation of analyses at the Women in Ophthalmology (WIO) Summer Symposium, which is taking place in Monterey, California from August 25-28, 2022.

August 25, 2022
·
9 min read
Biotech Beach

IN A RECENTLY PUBLISHED CLINICAL STUDY, COLORESCIENCE® TOTAL EYE® FIRM & REPAIR CREAM DEMONSTRATED SIGNIFICANT IMPROVEMENTS IN THE APPEARANCE OF OVERALL EYE AREA

Colorescience®, a leading dermatologist-recommended specialty skincare company, announces published results in the Journal of Cosmetic Dermatology, Efficacy and Tolerability of a Novel Skin Cream for Improving Periocular Rhytids and Dryness.

August 25, 2022
·
3 min read
Business

Wugen Appoints Natalie Mount, Ph.D., as Chair of the Board of Directors

Wugen, Inc. today announced the appointment of biotech executive and cell therapy veteran Natalie Mount, Ph.D., as Chair of the Board of Directors.

August 25, 2022
·
2 min read
Business

Biocytogen Expands Partnership with Merck KGaA, Darmstadt, Germany

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) entered into a global licensing agreement with Merck KGaA, Darmstadt, Germany, for the use of Biocytogen’s RenMice TM platform.

August 25, 2022
·
2 min read
Business

Kriya Appoints Curt Herberts as President and Chief Operating Officer

Kriya Therapeutics, Inc. announced today that it has appointed Curt Herberts, M.B.S., as President and Chief Operating Officer. Herberts will oversee all general and administrative functions at Kriya.

August 25, 2022
·
2 min read